pipeline-prospector-insert-v1
X

Find Oncology Drugs in Phase I/II Clinical Development in GERMANY

A collaboration with SCORR Marketing

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type

            Companies

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OR2805

            Therapeutic Area: Oncology

            Highest Development Status: Phase I/ Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: OncoResponse

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Collaboration January 16, 2020

            Details:

            Under the agreement, Just – Evotec Biologics will leverage its integrated technology platform, J.DESIGN, to provide OncoResponse with services to accelerate OR2805 into the clinic.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Autologous dendritic cell vaccine

            Therapeutic Area: Oncology

            Highest Development Status: Phase I/ Phase II Product Type: Vaccine

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 10, 2020

            Details:

            Final topline primary outcomes: DC vaccinations safe and feasible at 24 months of treatment Topline secondary outcomes: Overall survival rate of 80%, progression-free survival rate (PFS) of 55%.